Glabridin inhibits FAK and Src activation, blocks the FAK/Src complex, and suppresses the AKT and RhoA pathways, reducing cancer cell migration and invasion. It also limits tumor angiogenesis by inhibiting vascular endothelial cell tube formation. The gene discussed is RHOA; the disease is cancer.